During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.

Permira has signed a deal to acquire a majority stake in orthopedics group Corin from a group of investors for an undisclosed price.

Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.